AstraZeneca Operating Income 2010-2023 | AZN

AstraZeneca annual/quarterly operating income history and growth rate from 2010 to 2023. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
  • AstraZeneca operating income for the quarter ending December 31, 2023 was $1.234B, a 12.69% increase year-over-year.
  • AstraZeneca operating income for the twelve months ending December 31, 2023 was $8.193B, a 118.07% increase year-over-year.
  • AstraZeneca annual operating income for 2023 was $8.193B, a 118.07% increase from 2022.
  • AstraZeneca annual operating income for 2022 was $3.757B, a 255.78% increase from 2021.
  • AstraZeneca annual operating income for 2021 was $1.056B, a 79.54% decline from 2020.
AstraZeneca Annual Operating Income
(Millions of US $)
2023 $8,193
2022 $3,757
2021 $1,056
2020 $5,162
2019 $2,924
2018 $3,387
2017 $3,677
2016 $4,902
2015 $4,114
2014 $2,137
2013 $3,712
2012 $8,148
2011 $12,795
2010 $11,494
2009 $11,543
AstraZeneca Quarterly Operating Income
(Millions of US $)
2023-12-31 $1,234
2023-09-30 $1,954
2023-06-30 $2,456
2023-03-31 $2,549
2022-12-31 $1,095
2022-09-30 $1,245
2022-06-30 $539
2022-03-31 $878
2021-12-31 $-292
2021-09-30 $-1,674
2021-06-30 $1,127
2021-03-31 $1,895
2020-12-31 $1,487
2020-09-30 $1,171
2020-06-30 $1,284
2020-03-31 $1,220
2019-12-31 $577
2019-09-30 $757
2019-06-30 $493
2019-03-31 $1,097
2018-12-31 $1,077
2018-09-30 $851
2018-06-30 $763
2018-03-31 $696
2017-12-31 $686
2017-09-30 $1,149
2017-06-30 $925
2017-03-31 $917
2016-12-31 $2,533
2016-09-30 $1,028
2016-06-30 $303
2016-03-31 $1,038
2015-12-31 $1,088
2015-09-30 $1,170
2015-06-30 $923
2015-03-31 $933
2014-12-31 $-349
2014-09-30 $541
2014-06-30 $1,109
2014-03-31 $836
2013-12-31 $-591
2013-09-30 $1,706
2013-06-30 $1,200
2013-03-31 $1,397
2012-12-31 $1,964
2012-09-30 $2,156
2012-06-30 $1,868
2012-03-31 $2,160
2011-12-31 $2,167
2011-09-30 $4,262
2011-06-30 $2,965
2011-03-31 $3,401
2010-12-31 $2,829
2010-09-30 $2,406
2010-06-30 $2,868
2010-03-31 $3,391
2009-12-31 $2,963
2009-09-30 $3,145
2009-06-30 $2,537
2009-03-31 $2,898
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $212.533B $45.811B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $690.114B 114.92
Novo Nordisk (NVO) Denmark $550.665B 45.36
Johnson & Johnson (JNJ) United States $356.431B 14.14
Merck (MRK) United States $318.604B 83.85
AbbVie (ABBV) United States $294.653B 14.98
Novartis AG (NVS) Switzerland $200.005B 13.86
Pfizer (PFE) United States $147.226B 14.21
Sanofi (SNY) $117.121B 10.55
Innoviva (INVA) United States $0.945B 6.67